Aim: Randomized clinical trials and meta-analyses describe the benefit of chemotherapy and combined chemotherapy and radiotherapy for specific subgroups of major gastrointestinal (colorectal, pancreas, oesophagus, stomach, liver and gallbladder) cancer patients with selected patient and disease characteristics. This study estimates the overall survival benefit for the whole population of gastrointestinal cancer patients in Australia if evidence-based guidelines for chemotherapy were followed Methods: Decision trees with evidence-based indications for chemotherapy have been previously defined. Additional branches were defined in cases where new sub-groups benefit from chemotherapy. For all defined indications, the highest level of clinical evidence available was identified. Multiple electronic citation databases were systematically queried, including Medline and the Cochrane Library. In cases where there were multiple sources of the same level of evidence, hierarchical meta-analysis was performed. The benefits of chemotherapy were estimated for 1, 5 and 10-year survival. To assess the robustness of our estimates, sensitivity analyses were performed.
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